Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 30;16(1):99.
doi: 10.1186/s12957-018-1401-y.

Malignant adnexal tumors of the skin: a single institution experience

Tolutope Oyasiji  1 , Wei Tan  2 , John Kane 3rd  2 , Joseph Skitzki  2 , Valerie Francescutti  2 , Kilian Salerno  2 , Nikhil I Khushalani  2
Affiliations

Malignant adnexal tumors of the skin: a single institution experience

Tolutope Oyasiji et al. World J Surg Oncol. .

Abstract

Background: Malignant adnexal tumors of the skin (MATS) are rare. We aimed to measure the survival of patients with MATS and identify predictors of improved survival.

Methods: A retrospective review of MATS treated at our institution from 1990 to 2012.

Results: There were 50 patients within the time period. Median age was 59.5 years (range 22-95); primary site was the head and neck (52%); most common histologic subtypes were skin appendage carcinoma (20%) and eccrine adenocarcinoma (20%); and the vast majority were T1 (44%). Most patients (98%) underwent surgical treatment. Chemotherapy and radiation were administered to 8 and 14% of patients, respectively. Recurrence rate was 12%. Median OS was 158 months (95% CI, 52-255). OS and recurrence-free survival at 5 years were 62.4 and 47.4% and at 10 years 56.7 and 41.5%, respectively. Five-year and 10-year disease-specific survival (DSS) was 62.9%. Age > 60 years was an unfavorable predictor of OS (HR 12.9, P < .0008) and recurrence-free survival (RFS) (HR 12.53, P < .0003). Nodal metastasis was a negative predictor of RFS (HR 2.37, P < 0.04) and DSS (HR 7.2, P < 0.03) while treatment with chemotherapy was predictive of poor DSS (HR 14.21, P < 0.03).

Conclusions: Younger patients had better OS and RFS. Absence of nodal metastasis translated to better RFS and DSS. Lymph node basin staging is worth considering in the workup and treatment.

Keywords: Adnexal; Malignant; Skin; Survival; Treatment; Tumors.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The Institutional Review Board of the Roswell Park Cancer Institute approved the study.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Overall survival curve
Fig. 2
Fig. 2
Disease-specific survival curve
Fig. 3
Fig. 3
Recurrence-free survival curve
See this image and copyright information in PMC

References

    1. Martinez SR, Barr KL, Canter RJ. Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors. Arch Dermatol. 2011;147(9):1058–1062. doi: 10.1001/archdermatol.2011.229. - DOI - PubMed
    1. Waqas O, Faisal M, Haider I, Amjad A, Jamshed A, Hussain R. Retrospective study of rare cutaneous malignant adnexal tumors of the head and neck in a tertiary care cancer hospital: a case series. J Med Case Rep. 2017;11:67. doi: 10.1186/s13256-017-1212-8. - DOI - PMC - PubMed
    1. Leboit P, Burg G, Weedon D, Sarasin A. World health organization classification of tumors: pathology & genetics: skin tumors. Lyon: IARCPress; 2006.
    1. Blake PW, Bradford PT, Devesa SS, Toro JR. Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. Arch Dermatol. 2010;146(6):625–632. doi: 10.1001/archdermatol.2010.105. - DOI - PubMed
    1. Avraham JB, Villines D, Maker VK, August C, Maker AV. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes. J Surg Oncol. 2013;108(1):57–62. doi: 10.1002/jso.23346. - DOI - PubMed

MeSH terms